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SUMMARY The aim of the study was to examine the relative prevalence of 
dermatophytic, yeast and non-dermatophytic mould onychomycosis among 
diabetic patients, and to compare it with nondiabetic patients. The study included 
460 consecutive diabetic patients and the same number of nondiabetic age-
matched subjects attending dermatology clinics at Farwaniya Hospital, Kuwait, 
over a period of 4 years. All patients were examined clinically and mycologically 
for any evidence of onychomycosis. All cases of clinically suspected and/or 
mycologically proven onychomycosis were prescribed terbinafine tablets 
250 mg orally per day continuously for 6-12 weeks. The prevalence of 
clinical onychomycosis in the diabetic and control group was 18.7% (86 
cases) and 5.7% (26 cases), respectively. Elderly diabetic patients were at 
an increased risk of developing onychomycosis. Toenails were affected in 
54 (62.8%), fingernails in 20 (23.3%), and both fingernails and toenails in 
12 (14%) cases in diabetic group. Distal subungual onychomycosis was the 
most common clinical presentation, recorded in 67.4% of patients, followed 
by total dystrophic onychomycosis in 11.6% of patients. Culture positivity 
alone was seen in 16 (18.6%), both culture and KOH positivity in 52 (60.5%), 
and positive KOH alone in 10 (11.6%) cases; 8 cases had negative KOH 
examination and culture, but were PAS positive. Dermatophytes were the 
most common isolate. Seven percent cases treated for onychomycosis 
from the diabetic group were evaluated as unsuccessful (relapsed) at the 
end of the study. This study confirmed that diabetic patients are at a high 
risk of having or contracting onychomycosis. Onychomycosis was found to 
correlate significantly with increasing age and male gender. These findings 
reinforce the importance of attending to infections in diabetics to reduce the 
associated morbidity. Managing onychomycosis in diabetics may require 
systemic antifungal treatment, physical measures and patient education.
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IntRodUCtIon
Diabetes mellitus (DM) is a worldwide problem 
of increasing importance. The World Health Orga-
nization (WHO) estimates that the world population 
of diabetic individuals will double to over 200 mil-
lion people by the year 2010. Diabetes mellitus is 
an important predisposing condition for cutaneous 
infections, including onychomycosis (1). Onycho-
mycosis is one of the most common nail diseases 
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with the prevalence varying from 2.8% to 11.1% 
and determined by a plethora of factors like age, 
predisposing conditions, social class, occupation, 
climate, living environment and frequency of travel 
(2). Onychomycosis can have four major types of 
clinical presentations: distal subungual (the most 
common form of the disease), proximal subungual 
(the most common form found in patients with hu-
man immunodeficiency virus infection), and super-
ficial and total dystrophic onychomycosis (3). Ony-
chomycosis, a mycotic infection of the nail unit, is 
caused by three groups of fungi, namely dermato-
phytes, yeasts, and non-dermatophyte moulds (4). 
While the majority of onychomycoses are caused 
by dermatophytes (over 90% of onychomycoses 
are caused by two dermatophytes: Trichophyton 
rubrum and Trichophyton mentagrophytes), yeasts 
and non-dermatophyte moulds are the pathogens 
in about 7% of fungal nail infections (4).
It is well known that diabetic patients often 
have problems with their feet, mainly due to neu-
ropathy and arterial insufficiency. The risk of toe or 
lower leg amputation may be increased if fissures 
or traumatic ulcerations are followed by a second-
ary infection (5). Thus nail infections represent a 
risk factor in diabetic patients because of possible 
sequels (5-7). Infections are a common problem 
among diabetic patients and fungal infection con-
stitutes the most common type of infection that 
exceeds 50% of all types of infections in diabetic 
patients (5). Diabetics are at least twice as likely 
to suffer from onychomycosis as normal individuals 
(5,8). Diabetic patients with onychomycosis have 
a higher percentage of gangrene and/or foot ulcer 
(12.2%) compared to those without onychomyco-
sis (3.8%), i.e. a 3-fold higher risk (9).
As of 2007, Kuwait’s population is estimated to 
be roughly 3 to 3.5 million people; about 15% of 
the adult Kuwaiti population have type 2 diabetes, 
while type 1 diabetes is also a common chronic 
disease in Kuwaiti children (1).
We designed this study to find out more about 
the clinico-epidemiologic factors related to ony-
chomycosis in our significant diabetic population 
and to compare it with onychomycosis in nondia-
betic patients.
MAteRIAlS And MethodS
This prospective and comparative study was 
performed at Department of Dermatology, Far-
waniya Hospital, Kuwait. The Hospital Ethics 
Committee approved the study and all participants 
signed a written informed consent. During the 
period from January 2005 to December 2008 , pa-
tients with DM type 1 or 2 and older than 18 years 
were recruited from outpatient clinics; this group 
of subjects corresponded to 460 consecutive dia-
betic patients presenting for consultation for any 
dermatologic problem. Control group included the 
same number of nondiabetic age- and gender-
matched subjects presenting to our outpatient 
clinic. None of 920 subjects suffered from skin dis-
orders known to alter the nail aspect. None of the 
recruited subjects was known to be suffering from 
a dermatosis with a potential to involve the nails.
Demographic data on diabetic patients and 
controls were obtained from patient history and 
medical records. Age, gender, duration and type of 
diabetes, medications taken by the patient, fungal in-
fections at other sites, and mean blood sugar values 
over the last 6 months, socioeconomic factors (oc-
cupation, education level, income, hobbies, habits 
of nail cutting, and footwear), trauma to the nail, 
contact with pets/animals, and family history of 
fungal infection were the parameters recorded for 
each patient. History of associated medical illnesses 
such as hypertension, coronary artery disease, vas-
cular disease, peripheral neuropathy, nephropathy 
and retinopathy was also obtained. 
Clinical diagnosis of onychomycosis was made 
and the patients were classified according to the 
following four major clinical presentations of onyc-
homycosis. These types included distal subungual, 
proximal subungual, superficial, and total dystro-
phic onychomycosis. The number of nails and the 
area of nail plate involvement, and the severity of 
onychomycosis were recorded. The severity of ony-
chomycosis was evaluated globally for all nails as 
mild (<25% involvement or <4 nails involved), mod-
erate (26%-74% involvement or 5-8 nails involved), 
or severe (>75% involvement or >9 nails involved) 
(10).  
Patient nails were cleaned with a spirit swab, 
and nail scrapings were obtained with a number 
15 sterile scalpel blade. In patients with distal and 
subungual onychomycosis (DSO) or total dystro-
phic onychomycosis (TDO), the nail was scraped 
from diseased area and scrapings were also col-
lected from subungual debris. In patients with 
superficial white onychomycosis (SWO), minute 
scrapings were taken from the superficial layers of 
the affected parts of the nail plate. The nail clippings 
or scrapings were incubated in 40% potassium hy-
droxide for 30 minutes and examined under micro-
scope for the presence of fungal elements. Cul-
ture was done on both cycloheximide-supplement-
ed and cycloheximide-free Sabouraud’s agar media, 
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to identify dermatophytes and non-dermatophyte 
fungal pathogens, respectively. The cultures were 
carried out on all nail specimens obtained from 
patients in both diabetic and nondiabetic groups. 
Each set of medium was incubated at 25° C - 
37 °C and examined regularly for 4-6 weeks, for 
any growth. If there was no growth after 6 weeks, 
the result was reported as negative. Separate 
samples were also taken if there was fingernail 
involvement in addition to toenail onychomycosis, 
or if different clinical types were observed in the 
same patient. 
Onychomycoses were identified according to 
the nature of the fungus grown at culture. They 
were thus classified as dermatophyte, yeast or 
non-dermatophytic mould onychomycoses. When 
two distinct fungi were seen microscopically and 
isolated simultaneously from a nail sample, mixed 
fungal infection of the nail plate was diagnosed. 
Some onychomycoses remained unidentified be-
cause the culture remained negative. If neither 
microscopy nor culture yielded a diagnosis, his-
tological analysis of crushed nail plate clippings 
was used to determine whether the pathogen was 
fungus. Nail plate fragment was sent for histo-
pathologic examination in a 10% buffered formalin 
container. Periodic acid-Schiff (PAS) staining was 
done for all specimens. 
Terbinafine 250 mg tablet orally per day was 
prescribed for all clinically suspected and/or my-
cologically proven cases for 6-12 weeks (finger-
nails 6 weeks and toenails12 weeks). Clinical and 
mycological examinations were repeated at 36 
weeks after the end of treatment. The primary effi-
cacy parameter was mycological cure, defined as 
negative results on microscopy and fungal culture 
of samples taken from the target nail. Secondary 
efficacy parameters included clinical cure (100% 
clearing of the target toenail) and complete cure 
(mycological cure plus clinical cure). Cure rates 
were evaluated at the end of the study (week 48). 
Cases evaluated as unsuccessful at the end of the 
study but noted as cured before the final visit were 
accepted as “relapsed”. Laboratory tests including 
complete blood count and biochemical assays of 
liver enzymes, urea, creatinine and glucose lev-
els were studied before and at the end of therapy. 
Side effects such as gastrointestinal complaints, 
headache and skin eruptions were recorded.
Statistical analysis
Chi-square test was used to compare differ-
ences between diabetic and nondiabetic patients. 
Logistic regression models were used to measure 
the association between various groups (age, 
gender, severity, type of diabetes, etc.) and preva-
lence of onychomycosis in diabetic and nondia-
betic patients. The level of significance was set at 
P<0.05. 
ReSUltS
The study included 460 diabetic patients, 302 
(65.65%) men and 158 (34.35%) women, aged 
18-65 (mean age, 36.5) years. Of the 460 non-
diabetic controls, there were 276 (60%) males and 
184 (40%) females. Most of the recruited patients 
in both groups were in the 46-65 age group (Table 
1). Thirty six (7.8%) patients had type 1 diabetes and 
424 (92.2%) patients had type 2 diabetes.
The prevalence of clinical onychomycosis in 
diabetic and control groups (Table 1) was 18.7% 
(86 cases) and 5.7% (26 cases), respectively. The 
mean duration of nail involvement was 1.8 years 
in the diabetic group and about 8 months in the 
control group. The duration of diabetes in patients 
with onychomycosis was 9.1±0.9 years. In diabetic 
group, 34 (39.5%) patients with clinical onychomy-
cosis were in the 56-65 age group, followed by 24 
(28%) patients in the 46-55 age group. Similarly, in 
table 1. Age distribution of patients with clinical onychomycosis in diabetic and control groups
Age group
(yrs)
Diabetic group Control group
Total number of 
patients recruited
Patients with clinical 
onychomycosis
(n=86)
Total number of 
patients recruited




























Total 460 86 460 26
*P<0.05; **P<0.001
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control group, the frequency of clinical onychomy-
cosis was 46.2% (12 cases) and 23.1% (6 cases) 
in the 56-65 and 46-55 age groups, respectively. 
The presence of onychomycosis was found to cor-
relate significantly with increasing age (P<0.01) 
and male gender (P<0.05) in both diabetic and 
control groups.
Of the 86 cases with clinical onychomycosis 
in diabetic group, toenails were affected in 54 
(62.8%), fingernails in 20 (23.3%), and both fin-
gernails and toenails in 12 (14%) cases. In control 
group, the frequency of involvement of toenails, 
fingernails, and both toenails and fingernails was 
61.5% (n=16), 23.1% (n=6), and 15.4% (n=4), 
respectively. The degree of nail involvement was 
mild in 54.2%, moderate in 36.4% and severe in 
9.4% of patients with onychomycosis. Statistical 
analysis showed that there was no significant dif-
ference in the distribution and severity of onycho-
mycosis between cases and controls (P>0.1). In 
diabetic group with clinical onychomycosis, DSO 
was the most common clinical presentation, re-
corded in 67.4% (Table 2), and followed by TDO in 
11.6% of patients.
Of the 86 patients with clinical onychomycosis, 
culture positivity alone was seen in 16 (18.6%), both 
culture and KOH positivity in 52 (60.5%), and posi-
tive KOH alone in 10 (11.6%) cases; the remain-
ing 8 cases failed to show any fungal pathogens 
on KOH examination or on culture, but showed 
positive PAS stain on histopathologic examina-
tion. The distribution of fungal pathogens causing 
onychomycosis in diabetic group is shown in Table 
3, among cases where species identification from 
culture was possible. In diabetic group, dermato-
phytes were the most common isolate (53%), fol-
lowed by yeasts and moulds in 32.4% and 11.8%, 
respectively. In control group, the distribution of 
dermatophytes, yeasts and nondermatophyte 
moulds was 84%, 9.6% and 6.4%, respectively. In 
both diabetic and control groups, dermatophytes 
were the most common fungal pathogens isolated 
from toenails. However, yeasts were isolated more 
often from fingernails in diabetic group. Associ-
ated superficial fungal infections were present at 
other sites in diabetic and control groups in 40.4% 
and 4.6% of patients, respectively. The frequency 
of superficial fungal infections in diabetics with or 
without onychomycosis was significantly higher as 
compared with control group (P<0.001).
The type of DM was not a significant predic-
tor for the development and severity of onycho-
mycosis (P>0.01); however, both the prevalence 
and severity of onychomycosis were significantly 
more often associated with the duration of diabe-
tes (P<0.01). The mean blood glucose level in the 
preceding 6 months was not found to correlate 
significantly with the prevalence of onychomyco-
sis (P>0.01).  
The significant predictors for onychomycosis in 
diabetic patients included a family history of ony-
table 2. Distribution of clinical onychomycosis cases according to types of onychomycosis
Clinical type Diabetic patientswith clinical onychomycosisn (%)
Control group patients



















Total 86 (100) 26 (100)
DSO = distal subungual onychomycosis; PSO = proximal subungual onychomycosis; TDO = total dystrophic onycho-
mycosis; SWO = superficial white onychomycosis







   Trichophyton (T.) rubrum
   T. mentagrophytes
   T. tonsurans
   Microsporum gypseum
Yeasts
   Candida (C.) albicans
   C. tropicalis
Moulds
   Fusarium sp.
   Aspergillus niger
Mixed
   Trichophyton rubrum &
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chomycosis (P=0.0002), peripheral neuropathy 
(P<0.05), retinopathy (P<0.001), reduced or ab-
sent peripheral pulses in the extremities (dorsalis 
pedis or posterior tibial) (P<0.05), and concurrent 
intake of immunosuppressive therapy (P=0.030). 
However, various medical illnesses such as the 
history of hypertension, angina, myocardial infarc-
tion, hypercholesterolemia, intermittent claudica-
tion, and thyroid disorders were other non-signifi-
cant predictors for onychomycosis in both diabetic 
and nondiabetic groups (P>0.05). 
At the end of the follow up period (at week 48), 
mycological cure was obtained in 71.2% (47/66) 
and clinical cure in 62.1% (41/66) of diabetic pa-
tients treated with terbinafine for toenail infection; 
and in 81.3% (26/32) and 75% (24/32) of those 
treated for fingernail infection, respectively. The 
corresponding values for nondiabetic control group 
were 85% (17/20) of mycological cure and 70% 
(14/20) of clinical cure for toenail infections, and 
90% (9/10) of mycological cure and 80% (8/10) 
of clinical cure for fingernail infections (Table 4). 
Seven percent (6/86) of diabetic group cases, 6 
with toenail infection and 1 with combined toenail 
and fingernail infection, were evaluated as unsuc-
cessful (relapsed) at the end of the study. There 
was no relapse in control group.
At the end of treatment, laboratory data on both 
diabetic and nondiabetic patients proved to be 
practically unchanged for hematologic parameters 
such as creatinine, aspartate aminotransferase, 
γ-glutamyltransferase and alkaline phosphatase 
level. Glucose levels were unchanged after the 
12-week treatment period in all diabetic patients. 
No drug interaction, hypoglycemic episodes or 
reports of hypoglycemia were reported during the 
treatment. Therapeutic side effects (Table 5) were 
reported in 9 of 86 (10.5%) diabetic patients, and 
in 3 of 26 (11.5%) control patients. All side effects 
were minor, and none of the patients had to stop 
treatment due to side effects.
dISCUSSIon
Onychomycosis in diabetics is far from being 
just a cosmetic problem. On the contrary, it is a po-
tentially dangerous disease. It is known for quite 
some time that the morbidity linked to onychomy-
cosis, the ever-growing size of diabetic population 
and the high frequency of foot disorders in diabetic 
patients present a considerable health problem 
(11,12).
In the past, only a few studies determined the 
prevalence of onychomycosis in diabetic subjects 
(5,13-16). 
To our knowledge, this is the first study from Ku-
wait, which systematically determined the preva-
lence of and predisposing factors for the develop-
ment of onychomycosis in diabetic patients. In our 
study, the presence of onychomycosis was found 
to correlate significantly with increasing age and 
male gender in both diabetic and control groups. 
The increase in the prevalence of onychomycosis 
with advancing age has been reported previously 
(17,18). Elderly men with diabetes were particularly 
prone to the development of onychomycosis (10). 
Whether the increased prevalence of onychomy-
cosis in the elderly is related to changes in im-
munity or to an increased susceptibility due to dis-
eases such as DM is not well understood (10).  The 
increase in the number of cases with age may be 
table 4. Success rates of terbinafine treatment
Mycologic cure Clinical cure Relapse rate
Diabetic group
6/86 (7%)N (%) Toenail: n=66 47 (71.2%) 41 (62.1%)
N (%) Fingernail: n=32 26 (81.3%) 24 (75%)
Control group:
N (%) Toenail: n=20 17 (85%) 14 (70%)
N (%) Fingernail: n=10 9 (90%) 8 (80%)
table 5. Incidence of side effects
Side effect Diabetic group, n (%) Control group, n (%)
Gastrointestinal symptoms 5 (5.8%) 2 (7.7%)
Skin rash 1 (1.2%) 0
Disturbance of taste 3 (3.5%) 1 (3.8%)
Headache 3 (3.5%) 2 (7.7%)
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explained by repeated nail micro-trauma, due to 
a more prolonged exposure to pathogenic fungi, 
as well as greater work activity and venous insuf-
ficiency (19,20). 
In our study, onychomycosis was more frequent-
ly observed in toenails, followed by fingernails, in 
both groups, which is consistent with a study from 
India (10).
The diagnosis of onychomycosis can be made 
clinically most of the times, but laboratory stud-
ies are important to confirm the clinical diagno-
sis, and also to identify the etiologic agents (21). 
The efficiency of direct microscopic examination 
emphasizes the importance of the method, when 
performed by experienced professionals, favoring 
the speed of diagnosis and treatment of patients. 
This approach, together with culture is considered 
as an extremely important procedure for the epi-
demiological study of onychomycosis (21). In this 
study, dermatophytes were the most common iso-
late causing onychomycosis in diabetic patients, 
followed by yeasts and non-dermatophyte moulds. 
Other authors also isolated dermatophytes as the 
most common pathogens. However, in one Indian 
study, yeasts were found to be the most common 
pathogen causing onychomycosis in diabetic pa-
tients, followed by dermatophytes and non-der-
matophyte moulds (10). Another study from Saudi 
Arabia reports on Candida species as the most fre-
quently isolated pathogen from infected nails (22). 
Results of direct KOH examination correlated 
significantly with culture results in both diabetics 
and nondiabetics with onychomycosis, indicating 
KOH examination to have high sensitivity. Statistical 
analysis revealed that the probability of getting nail 
culture positive and direct KOH examination posi-
tive is the same in diabetics and nondiabetics with 
onychomycosis. There was no significant difference 
between diabetics and nondiabetics onychomyco-
sis patients according to the severity of nail involve-
ment. 
Among dermatophytes, T. rubrum, was isolat-
ed as the most common pathogen in both groups 
of patients, as also reported elsewhere (23,24).
In some patients, trauma was a predisposing 
factor, emphasizing its role in onychomycosis (25-
27). Peripheral neuropathy, impaired peripheral 
circulation, and retinopathy were observed to be 
significant predictors for the development of ony-
chomycosis in this study. Previous studies also cor-
related onychomycosis with diabetic complications 
of neuropathy, retinopathy, and impaired periph-
eral circulation (3,10). Thus, diabetic subjects with 
one or more predisposing factors for the develop-
ment of onychomycosis should have their feet and 
nails examined carefully and regularly. 
In our study, there was no correlation between 
the prevalence of onychomycosis and the mean 
blood glucose level over the last 6 months, which 
is consistent with earlier results (3,10). In the pres-
ent study, the prevalence and severity of onychomy-
cosis were significantly more often associated with 
the duration of diabetes. Thus, early intervention 
while onychomycosis is less severe may be advis-
able because of the potentially progressive nature 
of fungal infection (29). 
Terbinafine is currently the most active avail-
able antidermatophyte agent in vitro, and clinical 
studies strongly suggest that this is also the case 
in vivo (30). It has been reported to be superior 
to itraconazole, both in vitro and in vivo, for der-
matophyte onychomycosis (31). It is licensed at 
a dose of 250 mg daily for 6 and 12 weeks in fin-
gernail and toenail infection, respectively. A follow 
up period of at least 48 weeks from the start of 
treatment should be allowed both in order to allow 
the maximum effect to become apparent, and to 
identify relapse as far as possible.
A study of 104 diabetic patients treated with 
oral terbinafine 250 mg daily for 12 weeks showed 
a mycologic cure rate of 73% (32). Another study 
in diabetics of terbinafine 250 mg once daily for 
12 weeks showed mycologic cure in 79.3%, with 
no adverse events or medication interactions (33). 
In a study by Bohannon and Streja (34), the re-
sults in diabetic patients were compared with 
those recorded in a much larger group of nondia-
betic patients receiving terbinafine. There were 
no significant differences in mycological cure be-
tween diabetic and nondiabetic patients (64% vs. 
73%). The same trend was also observed for clini-
cal cure (37% vs. 45%).
At the end of treatment, laboratory data proved 
to be practically unchanged for hematologic pa-
rameters in both diabetic and nondiabetic patients. 
Laboratory examinations showed no abnormality 
including complete blood count and hepatic and 
renal functions. There were no drug interactions 
or reports of hypoglycemia during the treatment 
phase. Also, there were no significant side effects 
in the multicenter study by Farkas et al. (32), as 
only minor side effects were reported in 12% of 
cases. Adverse events were limited to gastroin-
testinal pain/upset, headache and taste changes. 
In 83% of patients, blood glucose levels remained 
the same as those at baseline, and there were no 
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episodes of hypoglycemia in patients with insulin 
dependent diabetes mellitus or non-insulin depen-
dent diabetes mellitus (32). We recorded a 7% re-
lapse rate in diabetic group only, with no relapse in 
control group, which may be due to recurrence/re-
infection. 
ConClUSIon
This study confirmed diabetic patients to be at a 
high risk of having or contracting onychomycosis. 
Onychomycosis was found to correlate significant-
ly with increasing age and male gender. Toenails 
were more commonly involved than fingernails in 
both diabetic patients and nondiabetic controls. 
The severity of onychomycosis is significantly as-
sociated with the duration of diabetes. Therefore, 
recognition and early intervention is advisable be-
cause of the potential progressive nature of fun-
gal infections and the potentially serious sequels 
associated with persistence of untreated infected 
nails. The consequences of neglecting onychomy-
cosis may carry more risk for diabetics compared 
with nondiabetic patients. Although it is the re-
sponsibility of the clinician to accurately diagnose 
and pertinently treat onychomycosis, education of 
diabetic patients about the importance of foot and 
nail care should form an essential component of 
diabetes management. This is especially impor-
tant in patient groups at a higher risk for the de-
velopment of onychomycosis, such as elderly dia-
betics, as found in the present study. In the group 
of non-insulin dependent DM patients taking oral 
antidiabetic agents and suffering from multiple 
concomitant diseases treated with different types 
of medication, most of the potentially serious drug 
interactions can be avoided with the appropriate 
selection of antifungal agent. 
Terbinafine has a relatively low risk of drug-drug 
interaction and has a proven efficacy against typi-
cal pathogens that cause onychomycosis, which 
makes it especially attractive for diabetic popula-
tion. Therefore, it should be the drug of choice in 
the treatment of onychomycosis in diabetics. Re-
lapse is more common in diabetic patients than in 
nondiabetic patients, so managing onychomyco-
sis in diabetics may require accompanying an an-
tifungal agent with mechanical/physical measures, 
and patient education regarding proper foot care 
to improve treatment outcomes and prevent recur-
rence. Nails should be cut short and kept clean, 
and the feet need to be dried completely following 
a bath or shower.
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